US subsidiary
Appears in 1 story · Last updated Sep 11, 2026
As of September 2026: Named applicant for OMCAZIO's US approval
The FDA cleared a Taiwanese drugmaker to sell an alternate-salt version of the $2.1 billion cancer drug cabozantinib in the United States. The final approval lands three days after a federal appeals court kept generic entry shut by upholding patents on the originator's salt form.
Updated Sep 11
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
